BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR |
|
|
| Recruiting | 2/3 | 3100 | Europe | Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax | University Hospital, Angers | Acute Myeloid Leukemia (AML) | 07/25 | 01/32 | | |
VITAL, NCT02658487: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia |
|
|
| Active, not recruiting | 2 | 42 | US | Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Vosaroxin, AG-7352, SNS-595, SPC 595, Voreloxin | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI) | Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Multilineage Dysplasia, Myeloid Sarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome | 04/19 | 09/24 | | |
2015-004066-28: A Phase II Study with a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2) - AMLSG 24-15 Studie mit einem Dosisfindungsteil gefolgt von einem Phase II-Teil zu Vosaroxin in Kombination mit Azacitidin bei Patienten mit akuter myeloischer Leukämie und intermediärem bzw. ungünstigem genetischem Risiko oder myelodysplastischen Syndrom mit Exzess von Blasten (MDS-EB-2) (AMLSG 24-15) |
|
|
| Not yet recruiting | 2 | 168 | Europe | Azacitidine, Vosaroxin, not applicalbe, Powder for injection, Injection, Vidaza | University Hospital Ulm, SUNESIS PHARMACEUTICALS, INC, University Hospital Ulm | Patients with confirmed diagnosis of acute myeloid leukemia (WHO 2016) and intermediate or adverse genetic risk (according to 2017 ELN recommendations); or patients with myelodysplastic syndrome with excess blasts-2 (MDS-EB-2) Patienten mit bestätigter Diagnose einer akuten myeloischen Leukämie (WHO 2016) und intermediärem oder ungünstigem genetischem Risiko (entsprechend den ELN Empfehlungen 2017); oder Patienten mit myelodysplastischem Syndrom mit Exzess von Blasten (MDS-EB-2), Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2) Patienten mit Neu diagnostizierte akute myeloische Leukämie oder myelodysplastisches Syndrom mit Exzess von Blasten (MDS-EB-2), Diseases [C] - Blood and lymphatic diseases [C15] | | | | |